Canine Lymphoma: Welfare Outcomes of Chemotherapy Treatment

Lymphoma is one of the most common cancers in dogs, and chemotherapy offers significantly extended welfare-positive life compared to no treatment, though treatment decisions are complex.

Key Facts

Lymphoma accounts for approximately 7-24% of all canine cancers and up to 83% of haematological malignancies
The CHOP protocol (cyclophosphamide, doxorubicin, vincristine, prednisone) achieves remission in 80-90% of cases
Median survival with CHOP is 12-14 months compared to 4-6 weeks without treatment
Dogs experience chemotherapy side effects but severe toxicity requiring hospitalisation occurs in under 5% of cycles
Quality of life during chemotherapy is good in most dogs who achieve complete remission

Welfare Considerations

Canine lymphoma without treatment causes rapid clinical deterioration through lymph node enlargement, systemic illness, and bone marrow compromise. Chemotherapy significantly extends life while maintaining good quality for most of this period, making it a welfare-positive intervention for many dogs. The CHOP protocol achieves remission in most cases with side effects that are generally mild and manageable. Dogs in complete remission show normal appetite, activity, and behaviour, indicating good welfare during treatment. Honest discussion of expected treatment course, side effects, and signs of deterioration enables owners to make welfare-centred decisions throughout the treatment period.

What You Can Do

Seek veterinary oncology assessment promptly when lymphoma is diagnosed in your dog
Discuss the CHOP protocol and expected welfare outcomes honestly with an oncologist
Monitor for chemotherapy side effects and report concerns promptly to your oncology team
Use validated quality of life assessment tools throughout treatment to inform ongoing decisions
Plan euthanasia timing proactively with your oncologist when lymphoma becomes refractory to treatment